Cardiovascular Risks Associated with Celecoxib
Absolute Contraindications
- The American College of Cardiology recommends avoiding celecoxib entirely in patients with established cardiovascular disease, congestive heart failure, or elevated cardiovascular risk 1
- The American College of Cardiology also recommends avoiding celecoxib in patients with recent myocardial infarction or unstable angina 2
- The American College of Cardiology warns against using celecoxib in patients with recent ischemic cerebrovascular events 2
Cardiovascular Risk Profile
- Meta-analysis data shows celecoxib increases the risk of myocardial infarction with an odds ratio of 2.26 (95% CI 1.0-5.1) compared to placebo 3
- Celecoxib increases serious vascular events with a rate ratio of 1.86 (95% CI 1.33-2.59) 3
Specific Concerns in Cardiac Disease Patients
Hypertension
- Celecoxib increases blood pressure by approximately 5 mm Hg on average 1
Heart Failure Risk
- The American College of Cardiology warns that celecoxib demonstrates an increased risk of hospitalizations for heart failure 1
- COX inhibitors can lead to impaired renal perfusion, sodium retention, and fluid accumulation 2
Risk Stratification Algorithm
- The American Heart Association estimates that in patients with prior myocardial infarction, the excess risk of mortality is 6 deaths per 100 person-years of treatment with a COX-2 inhibitor 2
If Celecoxib Must Be Used Despite Cardiac Disease
- The American Heart Association recommends using the lowest effective dose, preferably 400 mg once daily rather than divided doses 2
- The American Heart Association recommends using celecoxib for the shortest duration necessary to control symptoms 2, 1
Preferred Alternatives
- The American College of Cardiology recommends acetaminophen as a first-line treatment for patients with cardiac disease requiring pain management 6
- The American College of Cardiology recommends topical NSAIDs for localized pain as a second-line treatment 6
- The American College of Cardiology suggests considering naproxen, which has a more favorable cardiovascular profile among NSAIDs (rate ratio 0.92 vs placebo) 3